Abstract: Previous studies investigating the association between adenomatous polyposis coli (APC  ) gene promoter methylation and colorectal cancer (CRC) have yielded conflicting results. The aim of this study was to comprehensively evaluate the potential application of the detection of APC  promoter methylation to the prevention and treatment of CRC. PubMed, Embase, and MEDLINE (results updated to October 2014) were searched for relevant studies. The effect size was defined as the weighted odds ratio (OR), which was calculated using either the fixed-effects or random-effects model. Prespecified subgroup and sensitivity analyses were conducted to evaluate potential heterogeneity among the included studies. Nineteen studies comprising 2,426 participants were selected for our meta-analysis. The pooled results of nine studies comprising a total of 740 subjects indicated that APC  promoter methylation was significantly associated with CRC risk (pooled OR 5.53; 95% confidence interval [CI] 3.50–8.76; P <0.01). Eleven studies with a total of 1,219 patients evaluated the association between APC  promoter methylation and the presence of CRC metastasis, and the pooled OR was 0.80 (95% CI 0.44–1.46; P =0.47). A meta-analysis conducted with four studies with a total of 467 patients found no significant correlation between APC  promoter methylation and the presence of colorectal adenoma (pooled OR 1.85; 95% CI 0.67–5.10; P =0.23). No significant correlation between APC  promoter methylation and patients’ Dukes’ stage, TNM stage, differentiation grade, age, or sex was identified. In conclusion, APC  promoter methylation was found to be significantly associated with a higher risk of developing CRC. The findings indicate that APC  promoter methylation may be a potential biomarker for the carcinogenesis of CRC.
Keywords: APC  promoter methylation, colorectal cancer, meta-analysis